BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22167409)

  • 1. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
    Wang J; Guise CP; Dachs GU; Phung Y; Hsu AH; Lambie NK; Patterson AV; Wilson WR
    Biochem Pharmacol; 2014 Oct; 91(4):436-46. PubMed ID: 25130546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
    Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging tumor sensitivity to a bioreductive prodrug: two for the price of one!
    Brown JM
    Clin Cancer Res; 2012 Mar; 18(6):1487-9. PubMed ID: 22317761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
    Lee J; Siemann DW; Koch CJ; Lord EM
    Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia in human intraperitoneal and extremity sarcomas.
    Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
    Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
    J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
    Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
    Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
    Woods ML; Koch CJ; Lord EM
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
    Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
    J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
    Jenkins WT; Evans SM; Koch CJ
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering
    Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
    Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
    Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
    Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
    Hay MP; Shin HN; Wong WW; Sahimi WW; Vaz ATD; Yadav P; Anderson RF; Hicks KO; Wilson WR
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31295864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
    Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
    Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
    Evans SM; Jenkins WT; Joiner B; Lord EM; Koch CJ
    Cancer Res; 1996 Jan; 56(2):405-11. PubMed ID: 8542599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
    Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.